BCAX · Bicara Therapeutics Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| R&D | - | - | $33.00M | $15.80M | $12.00M | - | $6.90M |
| SG&A | $12.74M | - | $7.70M | $3.91M | $3.34M | - | $4.76M |
| Total Operating Expenses | $60.24M | - | $40.68M | $32.02M | $15.37M | - | $20.63M |
| D&A | $44.0K | - | - | - | $13.0K | - | - |
| Operating Income | ($60.24M) | - | ($40.68M) | ($19.75M) | ($15.37M) | - | ($20.63M) |
| Interest Expense | - | - | - | - | - | - | - |
| Income Tax | $52.0K | - | $40.0K | $0 | $1.0K | - | $0 |
| Net Income | ($56.21M) | - | ($36.33M) | ($27.39M) | ($36.85M) | - | ($22.84M) |
| EPS - Basic | ($0.93) | - | ($0.67) | ($0.50) | ($18.94) | - | ($1.60) |
| EPS - Diluted | ($0.93) | - | ($0.67) | ($19.01) | ($18.94) | - | ($1.60) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $323.46M | $96.69M | $171.67M | $436.61M | $462.06M | $489.71M | $520.76M |
| Accounts Receivable | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - |
| Current Assets | $544.91M | $422.05M | $297.37M | $444.39M | $470.75M | $502.53M | $521.51M |
| Total Assets | $553.60M | $430.99M | $424.69M | $453.59M | $478.08M | $510.00M | $233.98M |
| Current Liabilities | $39.34M | $28.95M | $21.03M | $17.23M | $19.12M | $17.99M | $15.09M |
| Long-term Debt | - | - | - | - | - | - | - |
| Total Liabilities | $39.64M | $29.54M | $21.91M | $18.39M | $19.12M | $18.12M | $14.62M |
| Stockholders' Equity | $513.96M | $401.45M | $402.78M | $435.20M | $458.96M | $491.88M | ($114.82M) |
| Retained Earnings | ($415.18M) | ($358.97M) | ($321.58M) | ($285.25M) | ($257.86M) | ($221.02M) | ($153.02M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($37.51M) | - | - | - | ($14.59M) | - | - |
| Investing Cash Flow | $100.94M | - | - | - | $58.0K | - | - |
| Financing Cash Flow | $163.34M | - | - | - | $137.0K | - | - |
| CapEx | $60.0K | - | - | - | $4.0K | - | - |
| Free Cash Flow | ($37.57M) | - | - | - | ($14.59M) | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross margin | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - |
| FCF / Net income | 0.67 | - | - | - | 0.40 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - |
| Return on assets | -10.2% | - | -8.6% | -6.0% | -7.7% | - | -9.8% |
| Return on equity | -10.9% | - | -9.0% | -6.3% | -8.0% | - | 19.9% |
| Return on invested capital | - | - | - | - | - | - | - |
| Liquidity | |||||||
| Current ratio | 13.85 | 14.58 | 14.14 | 25.80 | 24.62 | 27.93 | 34.57 |
| Quick ratio | 13.85 | 14.58 | 14.14 | 25.80 | 24.62 | 27.93 | 34.57 |
| Cash ratio | 8.22 | 3.34 | 8.16 | 25.34 | 24.17 | 27.22 | 34.52 |
| Leverage | |||||||
| Debt / Equity | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - |
| Equity multiplier | 1.08 | 1.07 | 1.05 | 1.04 | 1.04 | 1.04 | -2.04 |
| Liabilities / Assets | 0.07 | 0.07 | 0.05 | 0.04 | 0.04 | 0.04 | 0.06 |
| Efficiency | |||||||
| Asset turnover | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - |
| Valuation | |||||||
| P / E | - | - | - | - | - | - | - |
| P / B | 2.3x | - | 2.1x | 0.0x | 0.0x | - | - |
| P / S | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| Growth | |||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -291.8% | - | -97.2% | - | - | - | - |
| Net income growth (YoY) | -52.6% | - | -59.0% | - | - | - | - |
| EPS growth (YoY) | 95.1% | - | 58.1% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - |
| FCF growth (YoY) | -157.5% | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - |
| Book value growth (YoY) | 12.0% | -18.4% | - | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Bicara Therapeutics Inc. against the 5 most active filers in the same SIC group.